Corporation obtaining approval, the name of its representative, and the address of its main office

Name: Okayama University Hospital
Applicant: Kiyoshi Morita
Address: Shikata-cho 2-5-1, Okayama City

Approved Type 1 Use Regulation

| | |
|---|---|
| Name of the Type of Living Modified Organism | Nonproliferative and genetically modified human adenovirus type 5 that expresses interleukin 12 (Adv/IL12) |
| Content of the Type 1 Use of Living Modified Organism | Used in clinical facilities for human gene therapy, including storage, transportation, disposal and acts incidental to them |
| Method of the Type 1 Use of Living Modified Organism | Address: Shikata-cho 2-5-1, Okayama City, Okayama Prefecture<br>Name: Okayama University Hospital<br><br>(1) The Adv/IL12 solution should be sealed in containers, transported to a clinical facility in the frozen state, and stored in a deep freezer in a P2 level laboratory at the facility.<br>(2) Thawing, dilution and dispensing of the frozen Adv/IL12 solution must be performed in a safety cabinet in a P2 level laboratory. Storage of the diluted Adv/IL12 must be kept in a freezer in the P2 level laboratory. Note that when the diluted Adv/IL12 or its frozen form is transported to another P2 level area through an open area, it must be kept inside a container that is doubly sealed.<br>(3) When disposing of the solution (including dilutions) of Adv/IL12, these must be virally inactivated (by steeping in 0.5% sodium hypochlorite solution for 2 hours or longer) and disposed according to the infectious waste management protocol defined by the facility (hereinafter referred to as "the infectious waste management protocol").<br>(4) The diluted Adv/IL12 solution must be double-sealed and transported to the clean surgery room that is pressure-controlled not to be positive and has appropriate containment measures (hereinafter referred to as “clean surgery room”) or the room with a computed tomography system (hereinafter referred to as “CT room”). The solution must be filled up into the devices with ultrasound or CT guided injection needles, syringes, and tubes (hereinafter referred to as “injection device set”) connected to the injection pump.<br>(5) The administration of Adv/IL12 to a subject must be performed by injecting the diluted Adv/IL12 into the local reoccurrence of advanced prostate cancer in prostate that is resistant to endocrine therapy under ultrasound guide in the clean surgery room, or into the distant metastatic lesion under CT guide in the CT room, respectively.<br>(6) Following the administration of Adv/IL12, the wounds of the subject |

| | |
|---|---|
| | should be disinfected. The subject, who is wearing a mask and a dressing gown to prevent viral leakage, must be transfferd from the clean surgery room or CT room into a single room that is pressure-controlled not to be positive and has appropriate containment measures (hereinafter referred to as “single room”)<br>(7) The injection device set including dressing clothes and gauzes used in (5) and (6) described above must be disposed after the viral disinfection (by an autoclave or incineration) in accordance with the infectious waste management protocol. The injection guide equipments such as a pump, ultrasound system, must be reused after viral inactivation (by a cleaning with 20w/v/% of glutaraldehyde). These processes should be done in the clean surgery room or the CT room. The injection device set must be transported within a double-sealed container when the viral inactivation processes could be needed in an another open area.<br>(8) The subject should be cared for in the single room until 24 hours after administration. When the subject enters the open area outside the single room for examinations, etc., viral leakage prevention measures including the wearing of a mask and a gown must be compulsory.<br>(9) The excreta, etc. (including blood, body fluids, urine and feces) of the subject during the period of being taken care of in the single room should be virally inactivated (by steeping in sodium hypochlorite solution for 2 hours or longer, an autoclave or incineration) in the single room and disposed of in accordance with the infectious waste management protocol. If the viral inactivation is to be carried out in another area, the objects should be transported in a doubly sealed container. Note that the excreta, etc., from the subject that are to be used as clinical samples should be handled in accordance with the handling of the Adv/IL12 solution as described above.<br>(10) During the period of being taken care of in the single room, invasive devices that have been used in the subject and those that have been in contact with excreta, etc., must be virally inactivated and then be disposed of in accordance with the infectious waste management protocol, or be washed sufficiently in the single room. The devices must be transported within a double-sealed container when the viral inactivation processes could be needed in an another open area.<br>(11) Before releasing the subject from being taken care of in the single room, confirm that Adv/IL12 is negative in the blood and the urine of the subject. If Adv/IL12 is detected, the subject should continually be cared for in the single room.<br>(12) If Adv/IL12 is detected in the blood or the urine of the subject after releasing the subject from being taken care of in the single room, immediately transfer the subject to be taken care of in the single room, and take the same measures as in (8) to (11) above. |